Globus Medical: Q4 Earnings Insights
Portfolio Pulse from Benzinga Insights
Globus Medical (NYSE:GMED) reported Q4 earnings with an EPS of $0.6, missing estimates by 1.64% against an expected $0.61. Revenue increased to $342.04 million from the previous year. Despite beating EPS estimates in Q3 2023, the share price dropped by 0.69% the following day. The company's past earnings performance shows a pattern of fluctuating EPS and revenue figures.
February 20, 2024 | 9:40 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Globus Medical reported Q4 earnings with a slight miss on EPS estimates and a significant increase in revenue from the previous year.
The slight miss in EPS estimates may not significantly impact the stock price, as the increase in revenue indicates strong sales performance. However, historical data shows a drop in share price following earnings announcements, even after beating EPS estimates. This mixed performance makes the short-term impact uncertain, hence a neutral score.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100